Abstract

Objective: The involvement of Janus kinase2/signal transducer and activator of transcription (JAK2/STAT3) pathway reported in various solid tumors made authors study the conformational changes of JAK2-3e complex which was previously reported with a moderate percentage of In-vitro JAK2 inhibition.
 Methods: In this present study Compound 3e was reported with a moderate percentage of inhibition of JAK2 protein selected for performing molecular docking and molecular dynamics studies to elucidate the conformational changes with JAK2-3e complex. Docking studies were performed using ChemSketch to draw the structure of the compound and optimized/energy minimized using the Ligprep module of Schrodinger suite, employing optimized potentials for liquid simulations (OPLS-2005) force field. Molecular dynamics simulations were performed for 10 ns for complex using TIP4PEW water solvent model and neutralized by adding sodium ions.
 Results: Docking studies of Compound 3e which has been reported as one of the effective cytotoxic agents and a moderate percentage of In-vitro JAK2 inhibition among the series, showed H-bond interaction with leucine 855, serine936, aspartine994. Dock score and Ligand binding energy with protein suggested compound 3e has shown-4.049,-66.003 kcal/mol respectively. Molecular dynamics simulations elucidated the mechanistic insight of JAK-2 inhibition. The Root means square deviation (RMSD) pattern of both protein and ligands in the JAK2-3e complex observed to be different over 10 ns simulation. In the JAK2-3e complex, an exponential increase in RMSD of Cα and side-chain amino acids is observed during the first 1-3 ns simulation and is stabilized till 10 ns. During the 10 ns simulation, ligand 3e seems to be stable in the complex with an overall deviation<1 Å, despite a drastic increase between 1-3 ns. The ligand RMSD plot suggests that the ligand 3e remained intact within the binding site of the protein and longer time period simulation may elucidate the binding pattern and fate of ligand 3e.
 Conclusion: Results from molecular dynamics simulations elucidated the mechanistic insight of JAK-2 inhibition by 2, 4 disubstituted quinazoline compound that is N’(2-(4-nitrophenyl)quinazoline-4-yl) isonicotinohydrazide) and their binding phenomenon. Molecular docking studies further supported the elucidation of binding patterns of the molecules in the JAK-2 protein environment. Further simulations with a longer time period may provide deeper insights into ligand interactions in the protein environment. It is noteworthy to use compound 3e as a new scaffold for further development of multifunctional compounds.

Highlights

  • Cancer is one of the major threats to human life worldwide and is the second leading cause of death in the United States

  • We have designed a convenient Insilico method for one of the novel 2, 4 disubstituted quinazoline derivative that is N’(2-(4nitrophenyl)quinazoline-4-yl) isonicotinohydrazide) which was previously proved for their cytotoxic potentials

  • More hydrogen bond interactions are observed due to nitro substitution at the para position. In this present study Compound 3e from 2,4disubstituted quinazoline was reported with a moderate percentage of inhibition of JAK2 protein selected for performing molecular docking and molecular dynamics studies to elucidate the conformational changes and deeper insights with JAK2-3e complex

Read more

Summary

Introduction

Even cancer is the second most common cause of death among children aged 1-14 y in the United States. The sequence of events like cell cycle progression, cell division, and proliferation can be controlled by a cascade of enzymes such as protein kinases [2]. These enzymes are responsible for regulating physiological mechanisms, including cell differentiation, migration, and metabolism. These enzymes are divided into three categories like tyrosine kinases [3], serine/threonine kinases [4], and Histidine kinases [5]. The signaling pathways are responsible for bringing out these changes in breast and ovarian cells. There is a necessity to develop non-toxic and selective inhibitors of protein kinases in tumor cells represent the exciting targets for cancer treatment

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call